WAT · Earnings call · 2026Q2T · Full report
Pharma Reshoring Opportunity
WATERS CORP /DE/ · 2026-08-04 · Importance 44 · Surprise 24 · In source text
Waters is tracking 76 expansion sites tied to U.S. pharmaceutical investment announcements, with roughly half under active construction. Those sites represent approximately $100 billion of capital expenditures, and management expects instrument outfitting to create an Analytical Sciences revenue tailwind over the next three to five years. About 70% of the tracked sites are associated with existing high-share Waters customers, making the opportunity incremental in the short to medium term, particularly from 2027 through 2030.
Key facts
- Tracking 76 expansion sites linked to U.S. pharma investment announcements, roughly half under active construction representing approximately $100 billion in CapEx spend
- Approximately 70% of tracked reshoring sites are linked to customer accounts where Waters holds a high market share
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | — | Tracking 76 expansion sites linked to U.S. pharma investment announcements, roughly half under active construction representing… |
| revenue | positive | probable | — | Approximately 70% of tracked reshoring sites are linked to customer accounts where Waters holds a high market share |